TY - JOUR
T1 - The penetration of balofloxacin to sputum and its clinical effects on respiratory infectious diseases
AU - Ogasawara, Tomohiko
AU - Shimokata, Kaoru
AU - Senda, Kazuyoshi
AU - Minami, Hironobu
AU - Sakai, Shuzo
AU - Totani, Yasunobu
AU - Senda, Yoshihiro
AU - Imaizumi, Kazuyoshi
AU - Murate, Takanao
AU - Yurikusa, Naoko
AU - Takagi, Eishi
AU - Yamada, Yoshiyuki
AU - Kawabata, Atsushi
AU - Yamamoto, Masashi
AU - Katayama, Hiroshi
AU - Ohgimi, Tatsuo
PY - 1995
Y1 - 1995
N2 - A new oral quinolone drug, balofloxacin, was orally administered at a single dose of 100 mg to an elderly patient with bronchiectasis. The serum level increased with time from 0.26 μg/ml at 2 hours after administration to 1.54 μg/ml at 12 hours after administration. The sputum level also rose in approximately parallel with the serum level. The drug was also repeatedly administered, at a dose of 200 mg (in 2 divisions) or 400 mg (in 2 divisions), to 24 patients with respiratory infectious diseases. The efficacy was rated as excellent in 9 and good in 13, all of whom showed improvement in infectious symptoms (efficacy rate, 91.7%). The drug was particularly useful for 17 patients with pneumonia, who included 6 with mycoplasmal pneumonia; efficacy was excellent or good in all 17. Four of 5 pyogenic bacterial strains isolated were eradicated. Mild headache appeared in one patient as a side effect after 6 days of administration at 400 mg (in 2 divisions). Abnormal changes in clinical laboratory test values included elevated transaminases in 4, thrombocytosis in 1, and eosinophilia in 1, all of which were mild. These results suggest that this new quinolone drug, for oral use, is useful for treating respiratory infectious diseases, particularly pneumonia.
AB - A new oral quinolone drug, balofloxacin, was orally administered at a single dose of 100 mg to an elderly patient with bronchiectasis. The serum level increased with time from 0.26 μg/ml at 2 hours after administration to 1.54 μg/ml at 12 hours after administration. The sputum level also rose in approximately parallel with the serum level. The drug was also repeatedly administered, at a dose of 200 mg (in 2 divisions) or 400 mg (in 2 divisions), to 24 patients with respiratory infectious diseases. The efficacy was rated as excellent in 9 and good in 13, all of whom showed improvement in infectious symptoms (efficacy rate, 91.7%). The drug was particularly useful for 17 patients with pneumonia, who included 6 with mycoplasmal pneumonia; efficacy was excellent or good in all 17. Four of 5 pyogenic bacterial strains isolated were eradicated. Mild headache appeared in one patient as a side effect after 6 days of administration at 400 mg (in 2 divisions). Abnormal changes in clinical laboratory test values included elevated transaminases in 4, thrombocytosis in 1, and eosinophilia in 1, all of which were mild. These results suggest that this new quinolone drug, for oral use, is useful for treating respiratory infectious diseases, particularly pneumonia.
UR - http://www.scopus.com/inward/record.url?scp=0029558718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029558718&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1995.43.Supplement5_230
DO - 10.11250/chemotherapy1995.43.Supplement5_230
M3 - Article
AN - SCOPUS:0029558718
VL - 43
SP - 230
EP - 235
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
SN - 1340-7007
ER -